Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05253807 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration
A Phase 2 study of Non-small Cell Lung Cancer (NSCLC), sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 20
- Study locations
NCT05253807 is a Phase 2 study of Non-small Cell Lung Cancer (NSCLC) that has completed, run by Incyte Corporation. The registered enrollment target is 8 participants, below the 289-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT05253807, a Phase 2 study of Non-small Cell Lung Cancer (NSCLC), has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, single arm study to study the safety, efficacy and tolerability of Pemigatinib when used on participants with squamous or nonsquamous NSCLC with a documented FGFR1-3 mutations or fusions/rearrangement who have progressed on prior therapies and have no available standard treatment options
Conditions Studied
Interventions
- DRUG Pemigatinib
Study Locations (20)
Other
- H�PITAL NORD - CHU MARSEILLE - Marseille
- Chu de Toulouse Hopital Larrey Centre de Reference Des Maladies Rares de La Peau Service de Dermatol - Toulouse
- Zentralklinik Bad Berka Gmbh - Bad Berka
- Lungenklinik Hemer - Hemer
- Lki Lungenfachklinik Immenhausen - Immenhausen
- University Hospital Mannheim - Mannheim
- Irccs Centro Di Riferimento Oncologico - Aviano
- Istituto Tumori Giovanni Paolo Ii Irccs Ospedale Oncologico Bari - Bari
- Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori - Meldola
- Azienda Ospedaliera Universitaria San Luigi Gonzaga Orbassano - Orbassano
- Azienda Ospedaliera Di Perugia - Ospedale Santa Maria Della Misericordia - Perugia
- Azienda Ospedaliero Universitaria Pisana - Pisa
- Istituto Nazionale Tumori Regina Elena Irccs - Roma
Florida
- Florida Cancer Specialists & Research Institute - Fort Myers
- Miami Cancer Institute - Miami
- Memorial Healthcare System - Pembroke Pines
California
- Valkyrie Clinical Trials - Los Angeles
Kentucky
- University of Kentucky Hospital - Lexington
Pennsylvania
- Spoknwrd Clinical Trials Inc. - Easton
Tennessee
- Tennessee Oncology - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-04-29 |
| Est. Completion | 2023-08-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05253807
The ClinicalTrials.gov registry entry for NCT05253807 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 289-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (97% lower). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 1 intervention - of which Pemigatinib is the first listed.
NCT05253807 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, Florida, California.
Frequently Asked Questions
What is clinical trial NCT05253807 about?
NCT05253807 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration". This is an open-label, single arm study to study the safety, efficacy and tolerability of Pemigatinib when used on participants with squamous or nonsquamous NSCLC with a documented FGFR1-3 mutations or fusions/rearrangement who have progressed on prior therapies and have no available standard treatm...
What is the current status of trial NCT05253807?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2022-04-29. Estimated completion is 2023-08-16.
What conditions does trial NCT05253807 study?
This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC).
What interventions are being tested in trial NCT05253807?
The interventions under investigation include: Pemigatinib (DRUG).
Who is sponsoring clinical trial NCT05253807?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05253807 being conducted?
This trial has 20 study locations across California, Florida, Kentucky, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-small Cell Lung Cancer (NSCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer
RECRUITING · Phase 2
-
Pembrolizumab for Advanced NSCLC and PS 2-3
RECRUITING · Phase 2
-
Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC
ACTIVE NOT RECRUITING · Phase 2
-
PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung
ACTIVE NOT RECRUITING · Phase 2
-
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.